1142936-49-9 Usage
General Description
N-(5-(4-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide is a chemical compound with a complex structure that includes a triazolo and pyridin ring system. It also contains a cyclopropane and carboxamide functional group. N-(5-(4-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide is likely to have biological activity, potentially interacting with cellular proteins or enzymes given its complex structure. The presence of the hydroxymethyl and phenyl group suggests potential reactivity with other biomolecules. Further investigation and studies are needed to fully understand the chemical properties and potential applications of N-(5-(4-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide.
Check Digit Verification of cas no
The CAS Registry Mumber 1142936-49-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,2,9,3 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1142936-49:
(9*1)+(8*1)+(7*4)+(6*2)+(5*9)+(4*3)+(3*6)+(2*4)+(1*9)=149
149 % 10 = 9
So 1142936-49-9 is a valid CAS Registry Number.
1142936-49-9Relevant articles and documents
[1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof
-
, (2018/03/24)
The invention relates to a [1,2,4]triazol[1,5-a] pyridine compound as well as a preparation method and medical application thereof. Particularly, the invention relates to the compound shown in a general formula I, the preparation method of the compound, a
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
-
, (2015/09/22)
The present invention discloses pharmaceutical compositions comprising: a compound according to Formula I: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, d
FILGOTINIB: Tyrosine-protein kinase JAK1 inhibitor, treatment of rheumatoid arthritis, treatment of crohn's disease
Gras
, p. 547 - 551 (2014/12/11)
Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease, is associated with pain, progressive disability, systemic comorbidities and early death. Filgotinib (GLPG-0634), a new selective tyrosine-protein kinase (JAK1) inhibitor, is currently i
